Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tisento Therapeutics Inc. is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units and examiners, suggesting a range of subject matter within the portfolio.
WEDDINGTON, KEVIN E is the busiest examiner, currently managing 1 pending office action. This distribution shows that the workload is split among the assigned examiners, with no individual handling all pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031371 | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | FETTEROLF, BRANDON J | 70d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287616 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | WEDDINGTON, KEVIN E | 1629 | §112 | Final Rejection | — | Pending | Oct 19, 2023 |
| 18031371 | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | FETTEROLF, BRANDON J | 1626 | Other | Final Rejection | 70d | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTisento Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kevin E Weddington has the most, with 1 of Tisento Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
